[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604654":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":19,"responsibleParty":26,"collaborators":19,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":19,"eligibilityCriteria":36,"healthyVolunteers":32,"sex":37,"minAge":38,"maxAge":39,"enrollmentInfo":40,"targetDuration":19,"studyType":43,"phases":44,"briefSummary":46,"conditions":47,"keywords":50,"overallStatus":53,"whyStopped":19,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":61,"locationsCount":19},{"fullName":5,"class":6},"Assiut University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Terbinafine Hydrochloride Cream","EXPERIMENTAL","Participants diagnosed with otomycosis will receive topical terbinafine hydrochloride cream applied on an ear pack. The pack will be inserted into the external auditory canal and changed every 2 days for a total duration of 2 weeks.",[13],"Drug: Terbinafine Hydrochloride Cream",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Topical antifungal treatment. Terbinafine hydrochloride 1% cream will be applied on an ear pack, inserted into the external auditory canal, and changed every 2 days. Treatment continues for 14 days.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Doaa samy abdellatif, MBBCh","CONTACT","01099427096","nemo.memo19.nm@gmail.com",{"type":27,"investigatorFullName":28,"investigatorTitle":29,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Doaa Mohamed Samy Mohamed Abd Ellatief","resident , ENT","100604654","terbinafine-hydrochloride-for-the-treatment-of-otomycosis-100604654",false,"NCT07152327","Terbinafine Hydrochloride for the Treatment of Otomycosis","Effectiveness of Terbinafine Hydrochloride in the Treatment of Otomycosis: Basic and Clinical Evaluation","Inclusion Criteria:\n\n* Age ≥ 18 years (male or female).\n\nClinical diagnosis of otomycosis (presence of itching, ear discharge, ear canal debris, or fungal mass on otoscopic exam).\n\nConfirmation of fungal infection by direct microscopy (KOH preparation) and\u002For culture.\n\nWillingness to comply with study procedures and follow-up visits.\n\nProvided written informed consent.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n\nBacterial otitis externa, mixed bacterial-fungal infection, or chronic suppurative otitis media.\n\nHistory of ear surgery or tympanic membrane perforation.\n\nUse of systemic or topical antifungal agents within the last 2 weeks.\n\nKnown hypersensitivity or allergy to terbinafine or excipients of the study drug.\n\nImmunocompromised patients (e.g., HIV\u002FAIDS, chemotherapy, uncontrolled diabetes mellitus).\n\nPregnant or breastfeeding women.\n\nPatients unable or unwilling to provide informed consent or adhere to treatment protocol.","ALL","18 Years","65 Years",{"count":41,"type":42},50,"ESTIMATED","INTERVENTIONAL",[45],"NA","Otomycosis is a fungal infection of the ear that often causes itching, pain, ear discharge, and hearing problems. It is more common in hot and humid climates and in people with risk factors such as diabetes, frequent use of antibiotic ear drops, or swimming in polluted water. Standard treatments include antifungal ear drops, but relapses are frequent.\n\nThis study will evaluate the effectiveness of terbinafine hydrochloride cream, an antifungal medication, in treating otomycosis. Terbinafine is known to be active against fungi such as Aspergillus and Candida, which are common causes of ear fungal infections. In this study, patients with otomycosis will have terbinafine hydrochloride cream applied on an ear pack that will be placed in the ear canal and changed every two days for two weeks.\n\nThe main goal of the study is to find out whether terbinafine hydrochloride is effective in reducing symptoms and eradicating the fungal infection. Patients will be examined clinically and ear swabs will be tested before and after treatment. The study will be conducted at Assiut University Hospital and Assiut General Hospital in Egypt, and about 50 patients are expected to participate.",[48,49],"Otomycosis","Fungal Ear Infection",[48,51,52],"Aspergillus","Candida","NOT_YET_RECRUITING","2025-09-29",{"date":56,"type":57},"2025-10-01","ACTUAL",{"date":56,"type":42},{"date":60,"type":42},"2026-12-01",{"name":5,"class":6}]